Adam Martidis, MD
Retina Specialist · Colorado Springs, CONPI 1881697910
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.0%), consulting fees and other — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Genentech USA, Inc. at 48.8% of the total. Reporting peaked in 2023 at $6,500 and has fallen 81.4% since, to $1,208 in 2025.
Across 79 payments — averaging $189.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$7K
- US Retina LLC$4K
- Alcon$2K
- Amgen$268
- Alimera Sciences, Inc.$266
- AbbVie$192
- plus $884 from 11 others
Across 15 payments — averaging $2223.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$23K
- AbbVie$6K
- Amgen$4K
What the payments were for
- Consulting fees$5,04034%
- Food & beverage$5,70138%
- Ownership interest$9316%
- Other$3,32622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 25 | $7,321 |
| US Retina LLC | 3 | $4,444 |
| Alcon | 18 | $1,623 |
| Amgen | 3 | $268 |
| Alimera Sciences, Inc. | 5 | $266 |
| AbbVie(2 entities) | 7 | $192 |
| Harrow Eye, LLC | 2 | $161 |
| Eyepoint US, Inc. | 3 | $159 |
| Coherus Oncology, Inc. | 2 | $144 |
| Biogen | 1 | $133 |
| Astellas Pharma US Inc | 1 | $97 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Dutch Ophthalmic, USA | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Genentech, Inc. | 1 | $16 |
| Akorn, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,998 in reported general payments places this provider in the 80th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 132 | $4,043 |
| Ciprofloxacin Hcl | 115 | $1,257 |
| Latanoprost | 11 | $156 |
| Timolol Maleate | 14 | $110 |
| Brimonidine Tartrate | 20 | $98 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Colorado Springs
- James LuuColorado Springs$11K
- Cecinio RonquilloColorado Springs$10K
- Ramin SarrafizadehColorado Springs$6K
- Stanford TaylorColorado Springs$5K
- Mark ChittumColorado Springs$4K
- Amar ManninaColorado Springs$2K
- Jonathan WilliamsColorado Springs$367
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.